Story perspectives

Novartis’ GanLum Shows 97.4% Cure Rate for Malaria

11/14/2025

25 5

Summary

Story summary

Novartis reported Phase III results showing GanLum cures 97.4% of malaria cases, vs 94% for Coartem.
The 1,688-patient trial across 34 sites in 12 African countries demonstrated activity against drug-resistant parasites and rapid action against the transmission stage of the parasite.
The U.S. FDA granted GanLum Fast Track and Orphan Drug Designations; if approved, GanLum would be the first major malaria treatment since 1999, though lumefantrine resistance remains a concern.

1 of 1

Story summary

Novartis reported Phase III results showing GanLum cures 97.4% of malaria cases, vs 94% for Coartem.
The 1,688-patient trial across 34 sites in 12 African countries demonstrated activity against drug-resistant parasites and rapid action against the transmission stage of the parasite.
The U.S. FDA granted GanLum Fast Track and Orphan Drug Designations; if approved, GanLum would be the first major malaria treatment since 1999, though lumefantrine resistance remains a concern.